Morgan Stanley analyst Judah Frommer assumed coverage of Kymera Therapeutics (KYMR) with an Overweight rating and a price target of $70, down from $79. Healthy volunteer data with KT-621 “suggests a potential multi-blockbuster opportunity,” the analyst tells investors. Partnerships with Sanofi (SNY) and Gilead (GILD) further validate Kymera’s drug discovery and protein degradation capabilities, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics management to meet with B. Riley
- Kymera Therapeutics price target raised to $54 from $51 at BofA
- Kymera Therapeutics Announces Public Offering to Raise Funds
- Kymera Therapeutics Holds Annual Shareholder Meeting
- Kymera Therapeutics price target lowered to $53 from $56 at Oppenheimer